Cour Pharma, a biotech company, has signed a licensing agreement with Roche’s Genentech unit worth approximately $900 million. As part of the deal, Cour Pharma will develop its nanoparticle therapeutic technology in collaboration with Genentech to treat autoimmune disorders. The agreement is a significant milestone for Cour Pharma, which is now poised to receive development and commercialization support from Genentech, a leader in the biotech industry. The partnership is expected to enable Cour Pharma to accelerate the development of its autoimmune nanoparticle therapeutic program, which has the potential to exceed $940 million in value. By partnering with Genentech, Cour Pharma gains access to expertise, resources, and infrastructure to advance its product portfolio and drive it towards the market. This strategic partnership is a testament to the rapid growth and innovation in the biotech industry, with Cour Pharma’s technology and Genentech’s expertise coming together to tackle complex health challenges.
Source: https://www.chicagobusiness.com/health-care/cour-pharma-lands-licensing-agreement-roche-unit